Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature

Leuk Lymphoma. 2019 Jul;60(7):1827-1830. doi: 10.1080/10428194.2018.1562185. Epub 2019 Jan 7.

Authors

Elise Fournier^{1

2}, Luca Inchiappa³, Carole Delattre¹, Jean-Michel Pignon³, Frédérique Danicourt⁴, Maxime Bemba³, Catherine Roche-Lestienne^{5

6}, Agnès Daudignon⁵, Gauthier Decool^{2

6}, Christophe Roumier^{2

6}, Florent Dumezy^{2

6}, Loïc Fournier¹, Nathalie Grardel^{2

6}, Claude Preudhomme^{2

6}, Nicolas Duployez^{2

6}

Affiliations

¹ a Laboratory of Hematology , CH Dunkerque , Dunkerque , France.
² b Laboratory of Hematology , CHU Lille , Lille , France.
³ c Hematology Department , CH Dunkerque , Dunkerque , France.
⁴ d Pharmacology Department , CH Dunkerque , Dunkerque , France.
⁵ e Department of Medical Genetics , CHU Lille , Lille , France.
⁶ f INSERM UMR-S 1172 , University of Lille , Lille , France.

PMID: 30616415
DOI: 10.1080/10428194.2018.1562185

No abstract available

Publication types

Case Reports
Review

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antigens, CD19 / immunology*
Female
Gene Rearrangement*
Histone-Lysine N-Methyltransferase / genetics*
Humans
Immunotherapy / adverse effects*
Leukemia, Myeloid, Acute / chemically induced
Leukemia, Myeloid, Acute / pathology*
Middle Aged
Myeloid-Lymphoid Leukemia Protein / genetics*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Prognosis

Substances

Antibodies, Monoclonal
Antigens, CD19
CD19 molecule, human
KMT2A protein, human
Myeloid-Lymphoid Leukemia Protein
Histone-Lysine N-Methyltransferase